{"id":"tpn171h","safety":{"commonSideEffects":[{"rate":"0.1-1%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1-5%","effect":"Increased risk of genital yeast infections"},{"rate":"5-10%","effect":"Increased risk of hypotension"},{"rate":"0.1-1%","effect":"Increased risk of acute kidney injury"},{"rate":"10-20%","effect":"Increased risk of increased urination"},{"rate":"5-10%","effect":"Increased risk of dehydration"},{"rate":"1-5%","effect":"Increased risk of hypoglycemia"},{"rate":"10-20%","effect":"Increased risk of increased thirst"},{"rate":"10-20%","effect":"Increased risk of increased urination"},{"rate":"1-5%","effect":"Increased risk of electrolyte imbalance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TPN171H reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. TPN171H's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.","oneSentence":"TPN171H is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:24.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT06301854","phase":"PHASE3","title":"Long-term Safety of TPN171H Tablet in Erectile Dysfunction.","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2024-04-12","conditions":"Erectile Dysfunction","enrollment":472},{"nctId":"NCT04483115","phase":"PHASE2","title":"Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-11-16","conditions":"Pulmonary Arterial Hypertension","enrollment":60},{"nctId":"NCT05208814","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-03-31","conditions":"Pulmonary Arterial Hypertension, Erectile Dysfunction","enrollment":16},{"nctId":"NCT06090136","phase":"PHASE1","title":"Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-09-14","conditions":"Erectile Dysfunction","enrollment":12},{"nctId":"NCT06090123","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study for TPN171H","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-01-01","conditions":"Erectile Dysfunction","enrollment":24},{"nctId":"NCT05948644","phase":"PHASE1","title":"The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2019-04-08","conditions":"Pulmonary Arterial Hypertension","enrollment":10},{"nctId":"NCT04479917","phase":"PHASE2","title":"Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-07-23","conditions":"Erectile Dysfunction","enrollment":255},{"nctId":"NCT05750355","phase":"PHASE1","title":"Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-10-10","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT05188989","phase":"PHASE3","title":"Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2021-12-31","conditions":"Erectile Dysfunction","enrollment":765},{"nctId":"NCT05388825","phase":"PHASE2","title":"Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-08-01","conditions":"Erectile Dysfunction","enrollment":84},{"nctId":"NCT05585931","phase":"PHASE1","title":"Effect of TPN171H on Spermatogenesis","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-11-15","conditions":"Erectile Dysfunction","enrollment":18},{"nctId":"NCT05316428","phase":"PHASE1","title":"A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-02-24","conditions":"Alcohol, Phosphodiesterase Inhibitor, Erectile Dysfunction","enrollment":19},{"nctId":"NCT05185011","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2021-12-16","conditions":"Erectile Dysfunction, Pulmonary Arterial Hypertension","enrollment":24},{"nctId":"NCT04655872","phase":"PHASE1","title":"Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-11-26","conditions":"Healthy Male Subjects","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Simmerafil"],"phase":"phase_3","status":"active","brandName":"TPN171H","genericName":"TPN171H","companyName":"Vigonvita Life Sciences","companyId":"vigonvita-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TPN171H is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}